We evaluated the effect of nicardipine, a calcium channel blocker, on somatosensory evoked potentials (SEP) in 26 patients with acute cerebral infarction. Post treatment, 58% (15/26) of the N20 and P25 latencies were prolonged in the affected hemispheres; 8% (2/26) were shortened; and 35% (9/26) did not change. The mean N20 and P25 latencies were significantly prolonged two hours post treatment in the affected hemisphere (N20, P < 0-01, P25 P < 0O01). Nicardipine (Ni) had no effect on SEP components in the intact hemispheres. Needle electrodes were placed in Fpz, C3' and C4' (2 cm behind standard EEG C3 and C4), and the stimulating electrode was fixed to the skin over the median nerve at the wrist (electrode impedance 5 K). Stimuli were 0-2 ms square wave electrical pulses delivered with a frequency of 5 Hz and an intensity just above the thumb twitch threshold (current intensity 5-15 mA). The peak latencies of N20 and P25 components in the intact and affected hemispheres were recorded. At least three series of 256 responses were averaged for each side. The range of variability within individuals was less than 0 4 ms.
change. The mean N20 and P25 latencies were significantly prolonged two hours post treatment in the affected hemisphere (N20, P < 0-01, P25 P < 0O01). Nicardipine (Ni) had no The mean N20 and P25 latencies post-treatment were statistically significantly longer than pre-treatment in the affected hemispheres (N26 P < 0-01, P25 P < 0-01). There was no effect of nicardipine on SEP latencies in the intact hemispheres. In animal studies, if Ca+ +-antagonists were given pre-ischaemia or immediately post-ischaemia, outcome measures such as histology, cerebrospinal fluid (CBF), electrophysiological function, leaming ability, brain oedema, and mortality were often improved. However, when given post-ischaemia, the protective effect of Ca+ +-antagonists was absent and even negative results were observed.2 [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] Although Vorstrup et al found that nimodipine actually decreased cerebral blood flow (CBF) in the area of infarction in patients with acute ischaemic stroke,31 Gelmers et al2 reported that recovery of patients receiving oral nimodipine started up to 24 hours after acute ischaemic stroke was better than in control patients. Our results suggest that nicardipine possibly aggravated neuronal dysfunction in the affected hemisphere of patients when given one to seven days after ischaemic stroke. This result may have several explanations: 1) intracerebral "steal" of blood from ischaemic brain regions to areas of normal vascular reactivity where nicardipine causes vasodilation; 2) reduced CBF due to reduced BP and cerebral perfusion pressure; and 3) nicardipine therapy may have been given too late after stroke to reverse a transient ischaemic penumbra, or effectively limit calcium influx and its intracellular translocation.
In conclusion, our studies suggest that: 1) nicardipine prolongs the latency of SEP shortlatency components in ischaemic hemispheres when given one to seven days after acute ischaemic stroke, and also decreases BP; and 2) SEP measures might be useful as a convenient means to evaluate the effect of therapy on electrophysiological function and to provide a quantitative outcome measurement for clinical studies.
According to the results in the literature, we consider that it is possible that patients with acute infarction might benefit from treatment with a calcium antagonist if treatment could be -given before onset of the symptoms or within 24 hours after incident. The therapeutic use of calcium antagonist in acute ischaemic stroke needs more extensive experimental studies in various stroke models and clinical documentation in large-scale double-blind studies. 
